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and compare the economic costs and clinical outcomes associated with ranibi-
zumabmonotherapy versus laser photocoagulation alone for the treatment of DME
in Canada. METHODS: Cost-effectiveness of ranibizumab to a Canadian healthcare
systemwas analyzed using aMarkovmodel based on data from the RESTORE clinical
trial. After one year of treatment, the RESTORE trial reported a 6.1 (p0.0001) letter
improvement in best corrected visual acuity (BCVA) with ranibizumab compared to
laser photocoagulation. The model included 8 health states as defined by BCVA, and
followed a cohort of 63 year old patients with DME due to either type 1 or type 2
diabetes over a timehorizon to amaximumof 20 years. Year 1 health state transitions
andallhealthstateutilitieswerederived fromtheRESTOREtrial. Fromyear2onwards,
health state transitions were based on fixed probabilities of improving or worsening
BCVA. Resource use and costs were collected from the RESTORE trial, published liter-
ature, or standard Canadian sources. RESULTS: Compared to laser photocoagula-
tion, patients receiving ranibizumabmonotherapy accrued an additional 1.44 years
without legal blindness (BCVA 35 letters). Also, patients receiving ranibizumab
accrued an additional 0.19 quality-adjusted life years (QALYs) with a total incre-
mental cost of approximately $8,500, resulting in approximately $44,000 per QALY
gained. CONCLUSIONS: Compared to laser photocoagulation, ranibizumab mono-
therapy shows cost-effectiveness within commonly accepted cost per QALY
thresholds. In addition, this analysis predicts the use of ranibizumab for DME will
result in more years without legal blindness.
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OBJECTIVES: To evaluate the long-term health and economic outcomes of Insulin
Detemir (IDet) therapy in uncontrolled patients with type 2 diabetes mellitus
(T2DM) switching from insulin Glargine (IGlar) in the Chinese setting. METHODS:
Thepublished and validatedCOREDiabetesModelwas used tomake the long- term
(30 years) projection of health economic outcomes. The patient demographic in-
formation and clinical endpoints were derived from South Korea sub-analysis of
the PREDICTIVE trial. The study was a large, multi-centre, 6 months observational
study assessing the safety and efficacy of IDet. HbA1c was reduced of 0.2 %
(p0.05) by switching from IGlar to IDet. Baseline risk factors and racial character-
istic data were obtained from Chinese cohort studies. The market retail prices of
medications were calculated to estimate treatment costs. The diabetes manage-
ment and complications costs were obtained from Chinese published data and
adjusted to 2010 values using the Chinese Consumer Price Index. An annual dis-
counting rate of 3% was used for both health and economic outcomes. One-way
sensitivities analysis was performed. RESULTS: The treatment of IDet converted
from IGlar was projected to reduce the cumulative incidences of DM-related com-
plications. Background retinopathy, end-stage renal disease, ulcer, myocardial in-
farction events were reduced 0.685%,0.167%,0.243%,0.482% respectively. Therapy
conversion to IDet was projected to improve life expectancy by 0.061 year, and was
associated with improvements of 0.484 quality adjusted life year (QALY). The costs
of complicationswere reduced by CNY 5,595, resulting in a total directmedical cost
saving of CNY 2,869. CONCLUSIONS: Therapy conversion from IGlar to IDet in
T2DM patients could delay the onset of diabetes complications, was associated
with improvements in life expectancy and QALYs, and reduced direct cost over
patient lifetimes. IDet was shown to be a dominant treatment option in patients
with T2DM inadequately controlled with IGlar in Chinese setting.
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OBJECTIVES: The aim of this research was to assess the cost-effectiveness of phar-
maceutical care (PC) programme (relative to control) for patients with type 2 DM.
METHODS: A total of 222 patients were recruited at a pharmacist-managed diabe-
tes clinic of a government hospital in Malaysia and randomly allocated to inter-
vention and control group. Patients in the intervention group (n  111) were pro-
vided with PC, whereas, patients in the control group (n  111) received only the
usual pharmacy service. Clinical and economic outcomes of patients were evalu-
ated at baseline and after six months. RESULTS: There was no significant differ-
ence in the demographic and clinical characteristics at baseline between the inter-
vention and the control group. Significant reduction in glycosylated haemoglobin
(HbA1c) was observed frombaseline to 6-month in the intervention group. (Mean
standard deviations  9.93  1.76% versus 8.83  1.85%, p  0.05). Although the
total costs per patient were significantly higher for the intervention group
(RM681.07 versus RM542.64; p 0.014), the cost effectiveness ratio was lower in the
intervention group (RM619.15 versus RM3617.60/1% reduction in HbA1c). The in-
cremental cost-effectiveness ratio for HbA1c was RM145.72/%. CONCLUSIONS: In
conclusion, incorporation of PC into the management of type 2 DM can have a
definitive, positive impact on glycaemic control and lead to more cost-effective
treatment.
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OBJECTIVES: Physicians, Nursing Care Managers (CMs) and Dieticians are part of
the healthcare team looking after patients with diabetes mellitus at the 9 public
sector primary care clinics in the National Healthcare Group (NHG) in Singapore.
This paper studies the association between the level of glycaemic control and the
utilization of these professional services by type 2 diabetes mellitus (T2DM) pa-
tients at these clinics.METHODS: This study included all patients with T2DMwho
had attended the same clinics in 2009 for at least 12 months for the treatment of
diabetes. Data was extracted from the NHG Diabetes Registry (CDMS). The number
of outpatient clinic visits to the Physicians, CMs and Dieticians in a year was com-
pared by age and degree of glycaemic control using the mean glycated haemoglo-
bin (HbA1c) for the year, “Optimal” being 7%, “Acceptable” 7-9% and “Poor” 9%.
RESULTS: There were 58,057 T2DM patients with more females (54%) and dispro-
portionately more Indians (13%) and fewer Chinese (71%) than the general popula-
tion. Mean HbA1c was 7.421.27% which decreased gradually with age from 8.16%
(40 years) to 6.86% (90 years). The annual Physician attendances for diabetes
consult increased from 4.11.5 (“Optimal” HbA1c control) to 5.22.2 (“Poor” con-
trol), representing 85-89% of all Physician attendances for the year. Proportion of
patients seen by the CMs increased from 6.8% (“Optimal” control) to 52.5% (“Poor”
control), and similar for Dieticians, an increase from 1.3% (“Optimal” control) to
9.5% (“Poor” control). CONCLUSIONS: T2DM patients with “Optimal” glycaemic
control had significantly fewer clinic visits to the healthcare team than those with
“Poor” control, translating to lower overall healthcare costs for the patients and the
healthcare system. More attention is needed to improve the care of the patients
with “Poor” glycaemic control, in order to achieve better long-term health out-
comes and reduce healthcare utilization and costs.
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OBJECTIVES: Quick release (QR)-bromocriptine mesylate is a new treatment for
type 2 diabetes (T2DM) that has been shown to reduce HbA1c and cardiovascular
(CV)-related hospitalizations over one year. The objective of this study was to es-
timate the economic impact of (QR)-bromocriptine versus other oral antidiabetic
drugs as add-on therapy for patients who failed initial treatment. METHODS: A
decision-analysis model was designed to compare outcomes among QR-bro-
mocriptine, pioglitazone, rosiglitazone, and sitagliptin over one year when used as
add-on therapy. For each drug, changes in HbA1c levels were derived from product
labels and used to derive the expected number of hospitalizations for diabetes-
related complications based on published equations linking HbA1c levels to hos-
pitalizations. Rates of CV-related events (major adverse cardiac events, congestive
heart failure, angina, and revascularization) were extracted from clinical trial re-
ports of antidiabetic drugs in T2DM and were expressed on an annualized basis.
Hospital costs per admission were estimated from the Healthcare Cost & Utiliza-
tion Project, while drug costs were based on wholesale acquisition cost. A payer
perspective was assumed and direct medical costs were expressed in 2009 USD.
RESULTS: Patients treated with QR-bromocriptine had lower diabetes-related hos-
pitalization costs ($2,017) than those receiving rosiglitazone ($2,038), and higher
costs compared to pioglitazone ($1,928) and sitagliptin ($1,989). Patients receiving
QR-bromocriptine had lower CV-related hospitalization costs ($426) than those
treated pioglitazone, sitagliptin, or rosiglitazone ($523, $708, and $729, respec-
tively). Annual drug costs were lower for patients receiving QR-bromocriptine
($2,122) compared to pioglitazone ($2,605) and sitagliptin ($2,282) and higher than
for those receiving rosiglitazone ($1,977). Overall one-year costs were estimated to
be $4,565, $5,056, $4,979, and $4,745 for QR-bromocriptine, pioglitazone, sitagliptin,
and rosiglitazone respectively. CONCLUSIONS: Our findings suggest that, over one
year, T2DM patients treated with QR-bromocriptine as an add-on therapy are ex-
pected to have lower costs than those receiving pioglitazone, sitagliptin, and
rosiglitazone.
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OBJECTIVES: To examinemedication adherence amongMedicare Part D beneficia-
ries with diabetes and explore whether there is any association of usingmail-order
pharmacy (vs. retail pharmacy) with better adherence in this patient population.
METHODS:Using administrative pharmacy claims data, we conducted a retrospec-
tive cohort study on the Medicare Part D beneficiaries who newly initiated oral
anti-diabetic treatment between July 1, 2008 and December 31, 2008. The primary
outcome of interest was medication adherence to oral anti-diabetics during the
benefit year of 2009, which was measured using the proportion of days covered
(PDC). Mail-order pharmacy users were matched to retail pharmacy users via pro-
pensity scoring, controlling for patient’s demographic and clinical characteristics.
RESULTS: A total of 22,546 patients with diabetes were identified. The average PDC
was 0.60 and only 41.6% of the study populationwas adherent (defined as PDC0.8)
with oral anti-diabetic medications during calendar year 2009. The matched sam-
ple included 1361 patients from each cohort. Compared with the retail pharmacy
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